AstraZeneca's Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027 ...

Retrieved on: 2024-04-24 13:11:58

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027 .... View article details on hiswai:

Excerpt

Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData, comments: “Amidst this progress, AstraZeneca and Merck voluntarily withdrew ...

Article found on: www.globaldata.com